FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2517457772> ?p ?o ?g. }

• W2517457772 endingPage "416" @default.
• W2517457772 startingPage "411" @default.
• W2517457772 abstract "Mirabegron, the first selective β3-adrenoceptor agonist for the treatment of overactive bladder (OAB), inhibits cytochrome P450 isozyme CYP2D6. This study was performed in Japanese healthy postmenopausal female volunteers to assess any pharmacokinetic drug interaction between mirabegron and tolterodine, another OAB drug and a sensitive substrate of CYP2D6. Tolterodine 4 mg was orally administered from Days 1–7 and co-administered with mirabegron 50 mg from Days 8–14. Mirabegron 50 mg increased maximum concentration (Cmax) and area under the concentration-time curve from zero to 24 h after dosing (AUC24h) of tolterodine by 2.06-fold (90% confidence interval [CI] 1.81, 2.34) and 1.86-fold (90% CI 1.60, 2.16), respectively, and increased Cmax and AUC24h of the metabolite 5-hydroxymethyl tolterodine by 1.36-fold (90% CI 1.26, 1.47) and 1.25-fold (90% CI 1.15, 1.37), respectively. This suggested a weak pharmacokinetic drug interaction between mirabegron and tolterodine. Mean change from baseline of Fridericia's QT correction formula (ΔQTcF) was slightly higher on Day 14 than on Day 7. No subject had QTcF >480 msec or ΔQTcF >60 msec. All the treatment-emergent adverse events were mild. Mirabegron 50 mg was considered to be safe and well tolerated when coadministered with tolterodine 4 mg in healthy postmenopausal female volunteers." @default.
• W2517457772 created "2016-09-16" @default.
• W2517457772 creator A5009101660 @default.
• W2517457772 creator A5011176970 @default.
• W2517457772 creator A5017154746 @default.
• W2517457772 creator A5037341553 @default.
• W2517457772 creator A5052400661 @default.
• W2517457772 creator A5065661084 @default.
• W2517457772 creator A5073827693 @default.
• W2517457772 creator A5075689949 @default.
• W2517457772 creator A5077912421 @default.
• W2517457772 date "2016-12-01" @default.
• W2517457772 modified "2023-10-09" @default.
• W2517457772 title "Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females" @default.
• W2517457772 cites W1515159044 @default.
• W2517457772 cites W1557712130 @default.
• W2517457772 cites W1670451451 @default.
• W2517457772 cites W1963810625 @default.
• W2517457772 cites W1965724319 @default.
• W2517457772 cites W1970710807 @default.
• W2517457772 cites W1976690934 @default.
• W2517457772 cites W1986761759 @default.
• W2517457772 cites W1987980346 @default.
• W2517457772 cites W2005790995 @default.
• W2517457772 cites W2027905639 @default.
• W2517457772 cites W2034343992 @default.
• W2517457772 cites W2044865711 @default.
• W2517457772 cites W2044988410 @default.
• W2517457772 cites W2055149989 @default.
• W2517457772 cites W2057563553 @default.
• W2517457772 cites W2059240022 @default.
• W2517457772 cites W2060761223 @default.
• W2517457772 cites W2109298103 @default.
• W2517457772 cites W2123048529 @default.
• W2517457772 cites W2131449169 @default.
• W2517457772 cites W2146856638 @default.
• W2517457772 cites W2150233726 @default.
• W2517457772 cites W2312407032 @default.
• W2517457772 doi "https://doi.org/10.1016/j.dmpk.2016.08.002" @default.
• W2517457772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27829538" @default.
• W2517457772 hasPublicationYear "2016" @default.
• W2517457772 type Work @default.
• W2517457772 sameAs 2517457772 @default.
• W2517457772 citedByCount "8" @default.
• W2517457772 countsByYear W25174577722017 @default.
• W2517457772 countsByYear W25174577722018 @default.
• W2517457772 countsByYear W25174577722019 @default.
• W2517457772 countsByYear W25174577722021 @default.
• W2517457772 countsByYear W25174577722022 @default.
• W2517457772 countsByYear W25174577722023 @default.
• W2517457772 crossrefType "journal-article" @default.
• W2517457772 hasAuthorship W2517457772A5009101660 @default.
• W2517457772 hasAuthorship W2517457772A5011176970 @default.
• W2517457772 hasAuthorship W2517457772A5017154746 @default.
• W2517457772 hasAuthorship W2517457772A5037341553 @default.
• W2517457772 hasAuthorship W2517457772A5052400661 @default.
• W2517457772 hasAuthorship W2517457772A5065661084 @default.
• W2517457772 hasAuthorship W2517457772A5073827693 @default.
• W2517457772 hasAuthorship W2517457772A5075689949 @default.
• W2517457772 hasAuthorship W2517457772A5077912421 @default.
• W2517457772 hasConcept C112705442 @default.
• W2517457772 hasConcept C126894567 @default.
• W2517457772 hasConcept C142724271 @default.
• W2517457772 hasConcept C204787440 @default.
• W2517457772 hasConcept C22979827 @default.
• W2517457772 hasConcept C2778164427 @default.
• W2517457772 hasConcept C2778335254 @default.
• W2517457772 hasConcept C2778941218 @default.
• W2517457772 hasConcept C2781020410 @default.
• W2517457772 hasConcept C71924100 @default.
• W2517457772 hasConcept C98274493 @default.
• W2517457772 hasConceptScore W2517457772C112705442 @default.
• W2517457772 hasConceptScore W2517457772C126894567 @default.
• W2517457772 hasConceptScore W2517457772C142724271 @default.
• W2517457772 hasConceptScore W2517457772C204787440 @default.
• W2517457772 hasConceptScore W2517457772C22979827 @default.
• W2517457772 hasConceptScore W2517457772C2778164427 @default.
• W2517457772 hasConceptScore W2517457772C2778335254 @default.
• W2517457772 hasConceptScore W2517457772C2778941218 @default.
• W2517457772 hasConceptScore W2517457772C2781020410 @default.
• W2517457772 hasConceptScore W2517457772C71924100 @default.
• W2517457772 hasConceptScore W2517457772C98274493 @default.
• W2517457772 hasFunder F4320323024 @default.
• W2517457772 hasIssue "6" @default.
• W2517457772 hasLocation W25174577721 @default.
• W2517457772 hasLocation W25174577722 @default.
• W2517457772 hasOpenAccess W2517457772 @default.
• W2517457772 hasPrimaryLocation W25174577721 @default.
• W2517457772 hasRelatedWork W2001645992 @default.
• W2517457772 hasRelatedWork W2050061619 @default.
• W2517457772 hasRelatedWork W2084274868 @default.
• W2517457772 hasRelatedWork W2084288786 @default.
• W2517457772 hasRelatedWork W2136940899 @default.
• W2517457772 hasRelatedWork W2322724630 @default.
• W2517457772 hasRelatedWork W2581799300 @default.
• W2517457772 hasRelatedWork W2608412644 @default.
• W2517457772 hasRelatedWork W2890137344 @default.
• W2517457772 hasRelatedWork W2904063024 @default.

• next